In a significant development, Incyte announced on Saturday that its experimental medication for a chronic skin condition demonstrated long-term symptom relief in two advanced clinical trials. The drug, povorcitinib, was tested on patients suffering from moderate to severe hidradenitis suppurativa, a persistent skin disorder characterized by painful lumps, abscesses, and scarring, typically occurring in areas where skin folds such as the armpits and groin.
The newly presented data, shared at a recent medical conference, revealed that after 54 weeks of treatment, up to 71.4% of patients receiving povorcitinib experienced at least a 50% reduction in abscesses and inflamed skin nodules. Furthermore, the trials showed that as many as 57% of patients achieved significant symptom improvement, while up to 29% attained complete clearance of key skin lesions.
Povorcitinib is administered as a once-daily oral pill and functions by inhibiting JAK1, a protein that plays a crucial role in the inflammation process responsible for the painful abscesses and nodules. Current treatment options for hidradenitis suppurativa are limited and primarily consist of injectable medications. Presently, three drugs have received FDA approval for this condition: AbbVie’s Humira, Novartis’ Cosentyx, and UCB’s Bimzelx.
Notably, the most commonly reported side effects during the trials included acne, nasopharyngitis, and upper respiratory tract infections. Hidradenitis suppurativa affects approximately 1% to 4% of the U.S. population and disproportionately impacts individuals from racial and ethnic minority groups, as highlighted by the U.S. Food and Drug Administration.
Meanwhile, Incyte has confirmed that regulatory submissions for povorcitinib are currently under review by both the FDA and the European Medicines Agency, marking a crucial step toward potential approval and availability for patients.
